首页> 外文期刊>Gastrointestinal Endoscopy >Colorectal cancers not detected by screening flexible sigmoidoscopy in the prostate, lung, colorectal, and ovarian cancer screening trial
【24h】

Colorectal cancers not detected by screening flexible sigmoidoscopy in the prostate, lung, colorectal, and ovarian cancer screening trial

机译:在前列腺癌,肺癌,结直肠癌和卵巢癌的筛查试验中,通过筛查乙状结肠镜检查未发现结直肠癌

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Objective: Diagnosis of colorectal cancer after negative findings on endoscopic evaluation raises concern about the effectiveness of endoscopic screening. We contrast screening-detected cancers with cancers not detected by screening among participants assigned to flexible sigmoidoscopy (FSG) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial to determine the reasons for the lack of detection of prevalent lesions. Design: Cancers detected within 1 year of a screening FSG with abnormal findings were classified as screening detected. All other cancers were categorized, based on cancer stage and years until detection, as either not detectable or prevalent but not detected at the time of screening. Setting/Patients: A total of 77,447 subjects in the multicenter PLCO trial. Main Outcome Measurements: A total of 977 colorectal cancers were diagnosed with a mean follow-up of 11.5 years. Results: A total of 243 (24.9%) cancers were screening detected, 470 (48.1%) were not detectable at screening, and 264 (27.0%) were considered prevalent but not detected. Among prevalent nondetected lesions, 35.6% (n = 94) were attributed to problems in patient compliance (58 never screened, 34 delayed colonoscopy follow-up, and 2 inadequate bowel preparation), 43.9% (n = 116) were attributable to a limitation in the FSG procedure (97 beyond the reach of the sigmoidoscope and 19 inadequate depth of insertion on FSG), and 20.5% (n = 54) were caused by endoscopist limitation (33 missed on FSG, 21 missed at initial colonoscopy) (P <.0001). Had colonoscopy instead of FSG been used for screening, an additional 15.6% and as many as 19.0% of cancers may have been screening-detected. Limitations: These estimates are reasonable approximations, but biological variability precludes precise determinations. Conclusions: Prevalent nondetected cancers were more often attributable to problems with patient compliance or limitations in the FSG procedure than to missed lesions. Colonoscopy instead of FSG could have moderately increased the detection of cancer via screening.
机译:背景与目的:内镜评估阴性后大肠癌的诊断引起人们对内镜筛查有效性的关注。我们将筛查检测到的癌症与前列腺癌,肺癌,结肠直肠癌和卵巢癌(PLCO)筛查中分配给柔性乙状结肠镜检查(FSG)的参与者进行筛查未发现的癌症进行对比,以确定缺乏发现流行病灶的原因。设计:在筛查FSG的1年内检测到的具有异常发现的癌症被分类为检测到的筛查。根据癌症分期和直到检测的年限,将所有其他癌症分类为无法检测或普遍存在,但在筛查时未检测到。设置/患者:多中心PLCO试验中共有77,447个对象。主要指标:总共诊断出977个大肠癌,平均随访11.5年。结果:总共筛查了243(24.9%)个癌症,筛查时未检测到470个(48.1%),264个(27.0%)被认为是普遍但未检测到的癌症。在未发现的普遍病变中,有35.6%(n = 94)归因于患者依从性问题(58例从未筛查,34例结肠镜检查延迟随访和2例肠道准备不足),43.9%(n = 116)归因于局限性在FSG手术中(乙状结肠镜无法触及97处,在FSG上插入深度不足19处),内镜医师的局限性造成20.5%(n = 54)(FSG漏诊33例,初次结肠镜检查漏诊21例)(P < .0001)。如果使用结肠镜检查而不是FSG进行筛查,可能还会筛查出另外15.6%的癌症,多达19.0%的癌症。局限性:这些估计值是合理的近似值,但是生物学变异性无法进行精确的确定。结论:与漏诊病灶相比,未检出的常见癌症更容易归因于患者顺应性问题或FSG程序受限。结肠镜检查代替FSG可以通过筛选适度增加对癌症的检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号